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Recently published in Nature: Cell Death and Discovery,
Mahbub et al.1 have demonstrated that polyphenols can
synergistically enhance the action of the topoisomerase II
inhibitors: doxorubicin and etoposide in leukaemia cells. A
reduction of glutathione (GSH) was strongly associated with
sensitising cells to the pro-apoptotic effects of polyphenols
when used in combination with doxorubicin or etoposide.
Importantly, when polyphenols and topoisomerase II
inhibitors were combined, it was possible to induce a
synergistic decrease in cell proliferation (measured as ATP
levels), cell-cycle arrest and induction of apoptosis in
leukaemia cell lines.1
Five polyphenols that had been previously shown to induce
apoptosis in leukaemia cells (quercetin, apigenin, emodin,
rhein and cis-stilbene)2 were combined with doxorubicin or
etoposide in two lymphoid (CCRF-CEM and Jurkat) and two
myeloid (THP-1 and KG1a) cell lines. These cell lines were
selected as they had been identified as the most sensitive and
most resistant to polyphenol-induced apoptosis;2 in addition,
two non-tumour control haemopoietic stem cells (HSCs)
(CD133+ and CD34+) were investigated.
In the two lymphoid cell lines, it was shown that all studied
polyphenols when used in combination with each topoisome-
rase II inhibitor caused a synergistic or additive decrease
in cell proliferation, G2M or S phase cell-cycle arrest
and apoptosis. This was associated with a synergistic/additive
reduction of GSH levels, increased caspase 3, 8 and 9 activity,
and DNA damage (Figures 1a and b). In the non-tumour
control HCS cells the polyphenols had a protective effect;
following combination treatment with the topoisomerase II
inhibitors there was an increase in cell proliferation and a
decrease in apoptosis.
In myeloid cell lines there was a more differential effect:
when quercetin and apigenin were used in combination with
each topoisomerase II inhibitor, there was a synergistic/
additive decrease in cell proliferation, cell accumulation in
G2M and S phase of the cell cycle and an increase in
apoptosis. This was associated with decreased GSH levels,
increased caspase 3, 8 and 9 activity, and DNA damage
(Figure 1c). However, when emodin, rhein and to a lesser
extent cis-stilbene, were used in combination with each
topoisomerase II inhibitor, there was an antagonistic increase
in ATP, an inhibition of apoptosis and no cell-cycle arrest. This
was associated with an elevation of GSH levels and reduction
of caspase 3, 8 and 9 activity, and little or no DNA damage
(Figure 1d).
Examination of basal GSH levels showed that the levels in
the lymphoid leukaemia cell lines were significantly lower than
those of the non-tumour control HSCs and myeloid cell lines.
This could explain why the lymphoid cell lines are more
susceptible to polyphenol/topoisomerase II inhibitor treatment
compared with the myeloid cell lines. The identification of
GSH as a key player in the induction of apoptosis was first
highlighted by Franco and Cidlowski in 2009.3 Initially, GSH
depletion was considered as a by-product of ROS production
during mitochondrial permeability during apoptosis via the
intrinsic route;3 however, it is now clear that although
mitochondrial ROS formation is crucial for apoptosome
formation;4 reduced GSH is necessary for normal cells to
undergo apoptosis, independently of ROS.5 This led to the
suggestion that polyphenol-mediated decrease in intrinsic
GSH or efflux can sensitise lymphoid cancer cell lines to
topoisomerase II inhibitors, which results in the synergistic and
additive induction of apoptosis.
Although our in vitro studies in lymphoid leukaemia cell lines
suggest that the combination of polyphenols and topoisome-
rase II inhibitors may selectively enhance antitumour effects in
tumour versus normal HSCs, future in vivo studies are needed
to confirm that these effects are maintained in vivo. Where
enhanced activity is observed, translational studies need to
establish that enhanced activity is not counterproductive in
terms of just increasing drug potency and its associated side
effects, and hence no antitumour benefit.
In contrast, the differential effects seen in the myeloid cell
lines to polyphenol/topoisomerase II inhibitor combination
treatments can be attributed to changes in GSH levels. Where
myeloid cells were treated with quercetin and apigenin in
combination with topoisomerase II inhibitors, this caused a
depletion of GSH levels and the induction of apoptosis;
although antagonism of doxorubicin and/or etoposide was
observed with emodin, rhein and cis-stilbene, this occurred in
the presence of unchanged or elevation of GSH levels. This
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supports the idea that the elevation of GSH is linked to
chemotherapy resistance. Indeed high GSH levels are
commonplace in many cancer cells,6,7 and efflux of GSH is
considered to be key in the development of multi-drug
resistance.8 Furthermore, in myeloid leukaemia patients,
GSH levels and its associated enzyme GSH transferase are
commonly high, and are associated with increased risk of
disease relapse and resistance to chemotherapy treatments.9
The observed polyphenol-mediated antagonism of
topoisomerase II inhibitors in myeloid leukaemia cells is
especially important as polyphenols are abundant in a
balanced diet. This antagonistic effect of polyphenols has
been previously observed by Lui et al.,10 who showed that
quercetin antagonised the proteasome inhibitor bortezomib
(Velcade) in breast cancer cell lines, and raised the potential
negative effect of a polyphenol-rich diet with certain antitumour
regimes. The results of Mahbub et al.1 raise the possibility
of a similar effect in myeloid malignancies treated with
topoisomerase II inhibitors, in that dietary polyphenols may
prevent etoposide/doxorubicin-induced antitumour activity.
The mechanism of action of polyphenol-mediated antagonism
of topoisomerase II inhibitors is unclear. However, it is known
that GSH is contra-indicated for other chemotherapy agents,
such as for cisplatin, where GSH supplementation inhibits the
action of cisplatin. However, GSH-mediated depletion appears
unrelated to cisplatin insensitivity in myeloid leukaemia cell
lines.11 This is, however, in contrast to most other tumour
models, suggesting that alternate multi-drug resistance
mechanisms may be a feature of myeloid leukaemia cell lines.
Similarly, recent work has shown that antioxidants can
increase the metastasis of melanoma in mice,12 which raises
the possibility that in some cancer types, polyphenols and
Figure 1 A schematic showing the effects of topoisomerase II Inhibitors (doxorubicin or etoposide) alone and in combination with polyphenols (quercetin, apigenin, emodin,
rhein or cis-Stilbene) in lymphoid and myeloid leukaemia cells
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other antioxidants could be detrimental. Thus, it is funda-
mental to tailor any treatment, be it with novel antitumour
agents such as polyphenols or standard chemotherapy, to the
specific cancer types and investigate any possible treatment
interactions.
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